2022
Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.Peer-Reviewed Original ResearchSystemic therapyNational Comprehensive Cancer Network guidelinesMetastatic renal cell carcinomaStereotactic body radiation therapyMedian total doseClear cell histologyFirst-line therapyFrequent side effectsLines of therapyPreponderance of patientsRetrospective data collectionBody radiation therapyRenal cell carcinomaEfficacy of radiotherapyMRCC patientsMedian doseCell histologyNew regimensSystemic treatmentClinicopathologic characteristicsRT toxicityClinical benefitNetwork guidelinesSame therapyCell carcinoma
2020
Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).
Zengin Z, Dizman N, Salgia N, Jones J, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, Pal S. Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: e17100-e17100. DOI: 10.1200/jco.2020.38.15_suppl.e17100.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRelevant genomic alterationsRenal cell carcinomaGenomic alterationsCell carcinomaPathway alterationsCtDNA next-generation sequencingLines of therapyClear cell histologyMTOR pathway alterationsRate of concordanceCell histologyMedian ageSingle institutionTreatment sequencingClinicopathologic variablesCancer DatabaseCtDNA assessmentInvasive approachUrine specimenBlood specimensCtDNA studiesPatient databasePathogenic alterationsTumor DNA